Trials / Recruiting
RecruitingNCT06416410
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 392 (estimated)
- Sponsor
- Allist Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JAB-21822 | JAB-21822 administered orally as a tablet |
| DRUG | Tislelizumab | Tislelizumab administered as an intravenous (IV) infusion |
| DRUG | JAB-3312 | JAB-3312 administered orally as a tablet or capsule |
| DRUG | Pemetrexed | Pemetrexed administered as an intravenous (IV) infusion |
| DRUG | Carboplatin | Carboplatin administered as an intravenous (IV) infusion |
Timeline
- Start date
- 2024-08-07
- Primary completion
- 2026-09-30
- Completion
- 2027-02-28
- First posted
- 2024-05-16
- Last updated
- 2025-04-04
Locations
37 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06416410. Inclusion in this directory is not an endorsement.